# Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

> **NCT03522129** · PHASE1 · COMPLETED · sponsor: **Cognition Therapeutics** · enrollment: 3 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** CT1812
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03522129
- **Lead sponsor:** Cognition Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-30
- **Primary completion:** 2019-02-06
- **Final completion:** 2019-02-06
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03522129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03522129, "Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03522129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*